Ultragenyx

Sam Wadsworth, Ph.D., Chief Scientific Officer
Novato, CA
(NASDAQ: RARE)
Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. www.ultragenyx.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions